
|Articles|March 26, 2015
- Immunotherapy (Issue 5)
- Volume 5
- Issue 1
The Rationale for Immunotherapy in NSCLC
Author(s)Heather Wakelee, MD
Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).
Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).
<<<
Articles in this issue
about 11 years ago
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancersabout 11 years ago
Rich Immunotherapy Pipeline for Melanoma Under Wayabout 11 years ago
Tumor Antigens and Their Role in Immune Response in Melanomaabout 11 years ago
Major Programs Under Way in Immuno-Oncologyabout 11 years ago
PD-1 Inhibitors for Melanomaabout 11 years ago
Immunotherapy in GU Cancers































